blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2683383

EP2683383 - USE OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2-6-DIONE IN TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.10.2018
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  27.10.2017
FormerGrant of patent is intended
Status updated on  18.07.2017
FormerExamination is in progress
Status updated on  31.05.2017
FormerGrant of patent is intended
Status updated on  09.02.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901 / US
[2014/03]
Inventor(s)01 / GANDHI, Anita
37 Sterling Road
Bernardsville, NJ 07924 / US
02 / SCHAFER, Peter, H.
126 John E. Busch Ave.
Somerset, NJ 08873 / US
 [2014/03]
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2017/48]
Former [2014/03]Jones Day
Rechtsanwälte, Attorneys-at-Law Patentanwälte Intellectual Property Prinzregentenstraße 11
80538 München / DE
Application number, filing date12710411.509.03.2012
[2017/48]
WO2012US28538
Priority number, dateUS201161451995P11.03.2011         Original published format: US 201161451995 P
US201161480272P28.04.2011         Original published format: US 201161480272 P
[2014/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012125475
Date:20.09.2012
Language:EN
[2012/38]
Type: A1 Application with search report 
No.:EP2683383
Date:15.01.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 20.09.2012 takes the place of the publication of the European patent application.
[2014/03]
Type: B1 Patent specification 
No.:EP2683383
Date:29.11.2017
Language:EN
[2017/48]
Search report(s)International search report - published on:EP20.09.2012
ClassificationIPC:A61K31/495, A61P37/00
[2014/03]
CPC:
A61K31/517 (EP,CN,US); A61K31/495 (KR); A61B18/18 (US);
A61K31/196 (EP,US); A61K31/352 (EP,US); A61K31/4184 (EP,US);
A61K31/475 (EP,US); A61K31/704 (EP,US); A61K45/06 (EP,US);
A61P1/04 (EP); A61P1/08 (EP); A61P1/10 (EP);
A61P1/12 (EP); A61P11/00 (EP); A61P17/00 (EP);
A61P17/04 (EP); A61P17/14 (EP); A61P17/18 (EP);
A61P19/02 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P25/06 (EP); A61P25/08 (EP); A61P25/18 (EP);
A61P25/22 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P35/02 (EP); A61P35/04 (EP); A61P37/00 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P9/00 (EP);
G01N33/574 (CN); A61K2300/00 (US) (-)
C-Set:
A61K31/196, A61K2300/00 (EP,US);
A61K31/352, A61K2300/00 (US,EP);
A61K31/4184, A61K2300/00 (EP,US);
A61K31/475, A61K2300/00 (US,EP);
A61K31/517, A61K2300/00 (EP,US);
A61K31/704, A61K2300/00 (US,EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERWENDUNG VON 3-(5-AMINO-2-METHYL-4-OXOCHINAZOLIN-3 (4H) -YL) PIPERIDIN-2-6-DION BEI DER BEHANDLUNG VON IMMUNBEDINGTEN UND ENTZÜNDLICHEN ERKRANKUNGEN[2014/03]
English:USE OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2-6-DIONE IN TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES[2014/03]
French:UTILISATION DE 3-(5-AMINO-2-MÉTHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPÉRIDINE-2-6-DIONE DANS LE TRAITEMENT DE MALADIES LIÉES AU SYSTÈME IMMUNITAIRE ET INFLAMMATOIRES[2014/03]
Entry into regional phase02.10.2013National basic fee paid 
02.10.2013Designation fee(s) paid 
02.10.2013Examination fee paid 
Examination procedure02.10.2013Amendment by applicant (claims and/or description)
02.10.2013Examination requested  [2014/03]
03.07.2014Despatch of a communication from the examining division (Time limit: M06)
08.01.2015Reply to a communication from the examining division
23.10.2015Despatch of a communication from the examining division (Time limit: M04)
16.02.2016Reply to a communication from the examining division
10.02.2017Communication of intention to grant the patent
24.05.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
24.05.2017Fee for grant paid
24.05.2017Fee for publishing/printing paid
19.07.2017Communication of intention to grant the patent
20.10.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.07.2014
Opposition(s)30.08.2018No opposition filed within time limit [2018/45]
Fees paidRenewal fee
27.03.2014Renewal fee patent year 03
27.03.2015Renewal fee patent year 04
31.03.2016Renewal fee patent year 05
27.03.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.03.2012
AL29.11.2017
AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MK29.11.2017
NL29.11.2017
PL29.11.2017
PT29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
TR29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IE09.03.2018
LU09.03.2018
MT09.03.2018
IS29.03.2018
BE31.03.2018
[2020/33]
Former [2020/31]HU09.03.2012
AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
MK29.11.2017
NL29.11.2017
PL29.11.2017
PT29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
TR29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IE09.03.2018
LU09.03.2018
MT09.03.2018
BE31.03.2018
Former [2020/27]HU09.03.2012
AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
PT29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
TR29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IE09.03.2018
LU09.03.2018
MT09.03.2018
BE31.03.2018
Former [2020/16]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
TR29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IE09.03.2018
LU09.03.2018
MT09.03.2018
BE31.03.2018
Former [2020/08]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IE09.03.2018
LU09.03.2018
MT09.03.2018
BE31.03.2018
Former [2019/12]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IE09.03.2018
LU09.03.2018
BE31.03.2018
Former [2019/09]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
IE09.03.2018
LU09.03.2018
Former [2019/04]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
LU09.03.2018
Former [2018/52]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
MC29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SI29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/40]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RO29.11.2017
RS29.11.2017
SE29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/37]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
PL29.11.2017
RS29.11.2017
SE29.11.2017
SK29.11.2017
SM29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/35]AT29.11.2017
CY29.11.2017
CZ29.11.2017
DK29.11.2017
EE29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
RS29.11.2017
SE29.11.2017
SK29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/34]AT29.11.2017
DK29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
NL29.11.2017
RS29.11.2017
SE29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/24]AT29.11.2017
FI29.11.2017
HR29.11.2017
LT29.11.2017
LV29.11.2017
RS29.11.2017
SE29.11.2017
BG28.02.2018
NO28.02.2018
GR01.03.2018
Former [2018/22]FI29.11.2017
LT29.11.2017
NO28.02.2018
Cited inInternational search[A]WO2008039489  (CELGENE CORP [US], et al) [A] 1-14* paragraphs [5.17] , [ 5.59]; claim 18 *
by applicantUS3536809
 US3598123
 US3845770
 US3916899
 US4008719
 US5059595
 US5073543
 US5120548
 US5134127
 US5354556
 US5591767
 US5639476
 US5639480
 US5674533
 US5733566
 US5739108
 US5891474
 US5922356
 US5972891
 US5980945
 US5993855
 US6045830
 US6087324
 US6113943
 US6197350
 US6248363
 US6264970
 US6267981
 US6376461
 WO0232925
 US6419961
 WO02088171
 US6589548
 US2003133939
 US6613358
 US6699500
 WO2005037989
 US2005238646
 WO2006055689
 US7635700
    - HACHULLA E; LAUNAY D, "Diagnosis and classification of systemic sclerosis", CLIN REV ALLERGY IMMUNOL, (2010), vol. 40, no. 2, pages 78 - 83
    - WILEN, S. H. ET AL., TETRAHEDRON, (1977), vol. 33, page 2725
    - WILEN, S. H., Tables of Resolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268
    - "Systemic Lupus Erythematosus", HAHN BH, Harrison's Principles o_flnternal Medicine, MCGRAW-HILL, (2005), pages 1960 - 1967
    - JENS T. CARSTENSEN, Drug Stability: Principles & Practice, MARCEL DEKKER, (1995), pages 379 - 80
    - SEFTON, CRC CRIT. REF. BIOMED. ENG., (1987), vol. 14, page 201
    - BUCHWALD ET AL., SURGERY, (1980), vol. 88, page 507
    - SAUDEK ET AL., N. ENGL. J. MED., (1989), vol. 321, page 574
    - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138
    - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
    - AKHMETSHINA A. ET AL., ARTHRITIS RHEUM, (2009), vol. 60, no. 1, pages 219 - 224
 US20110451806
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.